Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

At the start of the month, the company spent $750 million to buy an early clinical-stage treatment that aims to treat a pair of B-cell cancers from Curon Biopharmaceutical. Given Merck's extensive ...

I believe both Merck and Pfizer deserve a buy rating with an upside into 2025 and beyond. An opportunity for investors to pick up shares in these two high-quality healthcare sector leaders trading ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Deutsche Bank lowered the firm’s price target on Merck (MRK) to $140 from $145 and keeps a Buy rating on the shares following the Q3 ...

We recently compiled a list of the 8 Most Undervalued Value Stocks To Buy According To Analysts. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against ...

With its portfolio of cancer medicines and one of the pharma industry's most recognizable names, it's no surprise that investors are curious about whether to buy shares of Merck (NYSE: MRK).

In my view, based on what's coming up for Merck, it's likely that investors with some patience will find the stock to be more appealing. Understanding the investment thesis for Merck requires ...